Summary The prognostic value of c-erbB-2 oncogene expression was studied retrospectively in a consecutive series of 230 node negative breast cancers, followed-up for at least 7 years after primary treatment. The expression of c-erbB-2 oncoprotein was determined on formalin-fixed paraffin-embedded tissue, using a monoclonal anti-c-erbB-2 antibody by the avidin-biotin immunoperoxidase method. Positive immunostaining was observed in 20.9% of cases, whereas strong diffuse positivity was recorded only in 8.7% of cases. C-erbB-2 gene product showed no association to T category or nuclear grade. A significant association of c-erbB-2 expression to prognosis was observed only for cases showing a strong diffuse immunostaining, but such an association was no longer statistically significant at multivariate analysis adjusting for other prognostic factors such as T category and nuclear grading. C-erbB-2 expression is of no value to predict the clinical course of node negative patients in the current practice.
Although node negative (N-) have a better prognosis with respect to node positive breast cancer patients, still they will recur in about 25% of cases in the first 10 years after surgery (Ciatto et al., 1990) . No adjuvant postoperative treatment was recommended in node-negative (N-) patients until a few years ago (National Institute of Health, 1986) , but recently many studies have been aimed at the identification of prognostic indicators allowing to select high-risk node-negative patients in whom adjuvant treatment may be worthwhile and cost-effective.
Proto-oncogenes have been studied with this purpose, and recently the amplification and overexpression of c-erbB-2 oncogenes have been demonstrated to be strongly associated with breast cancer aggressiveness in node-positive subjects (Slamon et al., 1987) . Further studies on this subject reported controversial results either demonstrating (Varley et al., 1987; Cline et al., 1987; Berger et al., 1988; Wright et al., 1989; Tandon et al., 1989; Lovekin et al., 1989; Paik et al., 1990; Querzoli et al., 1990) or denying (Van de Vijer et al., 1988; Barnes et al., 1988; Ali et al., 1988; Gusterson et al., 1988) the presence of such a prognostic association. No significant association of c-erbB-2 amplification and expression with prognosis has been observed for node-negative subjects in a limited number of studies (Barnes et al., 1988; Tandon et al., 1989; Paik et al., 1990; Gullick et al., 1991; Clark & McGuire, 1991) .
The c-erbB-2 oncogene encodes a 185-190 kilodalton transmembrane glycoprotein which has considerable homology with the epidermal growth factor receptor (Schechter et al., 1984; Coussens et al., 1985) , and a close association has been demonstrated between gene amplification, as determined by Southern blotting, and protein expression, as determined immunohistochemically (Berger et al., 1988) . In the present study c-erbB-2 expression has been retrospectively investigated by an immunohistochemical method in a consecutive series of node negative breast cancer cases, to determine its prognostic value and its reliability as a discriminant factor for adjuvant treatment in these patients. Routinely formalin-fixed, paraffin embedded specimens were obtained from the archives of the Institute of Pathology of Florence University. Sections were cut at 5 jsm, mounted on poly-L-lysine coated glass slides and air dried overnight at 37'C. Sections were deparaffinised through xylene and graded alcohols and treated for 10' at room temperature with absolute methanol and 0.5% hydrogen peroxide to block endogenous peroxidase activity. Sections were then washed in phosphate buffered saline (PBS, pH 7.4) and normal horse serum (Vector Laboratories, Burlingame, Ca, USA) was applied for 20' to reduce nonspecific antibody binding. CerbB-2 protein expression was investigated with the specific monoclonal mouse antibody mAbl (Triton Diagnostic, Alameda, Ca, USA), an IgGl immunoglobulin which recognises the external domain of the c-erbB-2 gene product. Sections were incubated overnight at 4'C with mAbl, at a concentration of 2.5fLgml-'. For negative controls the primary antibody was omitted (Barnes et al., 1988; Lovekin et al., 1989 (Figures 1 and 2 ) -as suggested by Soomro et al. (1991) . Grade attribution was blind of patient's status and previously assessed nuclear grade. Intraobserver repeatibility in the attribution of immunostaining degree was determined at a second reading of the whole series, after random admixturing of cases.
Material and methods
The association between T category, nuclear grade and c-erbB-2 grade was studied by the chi-square test. Statistical significance level was set at P<0.05. As regards c-erbB-2 expression, in addition to the conventional negative (grade 0) and positive (grade 1-3) categories, we also compared strongly positive immunostaining category (grade 3) vs other grades (0-2).
Univariate analysis of the relation of c-erbB-2 grade, T category (Tx cases were censored) and nuclear grade to relapse-free and overall survival was performed. Five-, sevenand ten-year survivals were determined according to Kaplan and Meier (1958) and significant differences between survival curves were checked by the log rank test.
Multivariate analysis of the association of different variable to survival (Cox, 1972) was performed. Variables entering the proportional hazards regression model were those which resulted to be associated to survival at univariate analysis.
negative cases and a significantly worse prognosis was evident only for subjects showing a strong (grade 3) c-erbB-2 positivity. A Kaplan-Meier plot of survival curves for c-erbB-2 categories is shown in Figure 3 and Figure 4 . Not all subjects had been followed for 10 years, and the significance of differences in survival curves observed at 5 years decreased at longer follow-up as the number of exposed subjects decreased. Table IV shows the results of multivariate analysis of the association of different variables to disease-free survival. T category confirmed its independent significant association to survival after simultaneous adjustment for potential confounders, whereas no independent association was observed for nuclear grade, or c-erbB-2 grade.
Discussion
Many reports on the possible prognostic role of c-erbB-2 expression in node negative patients have been published and although the results are controversial, the overall impression which can be drawn is that the prognostic importance of c-erbB-2 in this subset of patients is at best slight. of disease-free survival curves for C-erbB-2 is expressed relatively infrequently and because node negative have a better prognosis compared to node positive patients, relapses and deaths are less frequent. Statistical significance is dependent upon the number of events in the study and it is to be expected that a large number of relatively small studies would be affected by such a bias, with some by chance getting larger effects and so being likely to show statistical significance, and others by chance observing a smaller, non significant effect. This should not by itself be taken to imply any conflict between studies. Such a bias affects also the present study: in fact, although this is one of the larger consecutive series of node negative patients reported so far (Clark & McGuire, 1991) , a c-erbB-2 expression was observed in a minority of cases showing a limited number of events, thus allowing for a wide statistical variation of observed results.
Results
A significant association to prognosis was observed only for a small subset (8.7%) of cases, showing strong diffuse immunostaining. This finding may suggest that prognosis is better predicted by the degree of expression of c-erbB-2. Although intraobserved repeatibility was high in the present study, subjective assessment of the degree of staining in clinical practice remains unreliable. If the degree of expression is important then objective molecular biological techniques would be required for quantification.
However, the observed association of strong diffuse immunostaining with a worse prognosis was not independent of other prognostic indicators, as shown during multivariate analysis, and the finding has no clinical relevance, as only eight out of 67 total recurrences did occur in this subset of patients.
In conclusion, the findings of the present study, in accordance with other reports (Clark & McGuire, 1991; O'Reilly et al., 1991; Perren, 1991) , suggest that c-erbB-2 expression has a very limited prognostic value in node negative breast cancer and cannot be used in current practice to predict the clinical course of these patients. Larger studies or ultimately meta-analysis will be required to clearly demonstrate its prognostic significance. 
